Axi-cel in relapsed or refractory large B-cell lymphoma
Dr Jason Westin, hematologist at Texas MD Anderson Cancer Center, Houston gives insight into the overall survival findings from the ZUMA-7 trial of axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma. He shares his view on the implications of these findings on the treatment landscape. He also briefly discusses the design of the ZUMA-23 trial, a global, phase 3 study evaluating axicabtagene ciloleucel as first-line therapy in patients with high-risk large b-cell lymphoma that is currently recruiting.
With the educational support of:
